Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
ALX Oncology Holdings ( (ALXO) ) just unveiled an announcement.
On January 16, 2025, ALX Oncology Holdings Inc. adopted the 2025 Inducement Equity Incentive Plan, reserving 1,500,000 shares of common stock for equity awards without stockholder approval as per Nasdaq rules. This plan aims to attract new employees by offering equity-based awards similar to the company’s 2020 plan, aligning with Nasdaq’s inducement award exception, and potentially impacting the company’s talent acquisition and retention strategy.
More about ALX Oncology Holdings
ALX Oncology Holdings Inc. operates in the biotechnology industry, focusing on developing innovative therapeutics to enhance the immune system’s ability to combat cancer. The company is centered on improving the efficacy and safety of cancer treatments through its proprietary technology and research initiatives.
YTD Price Performance: 4.49%
Average Trading Volume: 1,021,207
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $85.97M
See more data about ALXO stock on TipRanks’ Stock Analysis page.
